Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to data from two Phase 1/2 trials. The trial findings were reported in “Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma,” a study published in the Journal of Clinical Oncology. Chimeric antigen receptor T-cell therapy, more commonly known as CAR-T cell therapy, is a…
You must be logged in to read/download the full post.
The post Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial appeared first on BioNewsFeeds.